Understanding how a specific mutation leads to blood cancers.
Molecular Basis for Progression of Myeloproliferative Neoplasms Induced by JAK2V617F
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11057744
This study is looking into how a specific gene mutation affects blood cancers called myeloproliferative neoplasms (MPNs) and aims to find new ways to improve treatments, which could help patients like you feel better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11057744 on ClinicalTrials.gov |
What this research studies
This research investigates the molecular mechanisms behind myeloproliferative neoplasms (MPNs), a group of blood cancers characterized by the overproduction of blood cells. It focuses on the JAK2V617F mutation, which is prevalent in many cases of these conditions, and aims to identify new therapeutic targets to improve treatment outcomes. By studying the deletion of chromosome 20q and its role in the progression of these cancers, the research seeks to uncover potential tumor suppressor genes that could lead to better therapies. Patients may benefit from insights that could lead to more effective treatments for MPNs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with the JAK2V617F mutation.
Not a fit: Patients with other types of blood cancers that do not involve the JAK2V617F mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that more effectively treat myeloproliferative neoplasms.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways in blood cancers, indicating potential for success in this area.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOHI, GOLAM — UNIVERSITY OF VIRGINIA
- Study coordinator: MOHI, GOLAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: blood cancer